'Practical and helpful clerks" provide a "smooth and personable service.'
Chambers and Partners 2011
'8 New Square successfully parlays its renowned IP expertise into success in the IT sector.'
Chambers & Partners (Information Technology) 2009
'An incredibly good set for IP matters'.
Legal 500 2010
'clerking team that exhibits 'perfect communication''
Legal 500 2008
'excellence on IT matters'
Legal 500 (Information Technology) 2010
'outstanding IP chambers'
Legal 500 2008
'A veritable powerhouse of IP expertise'
Chambers and Partners 2011
'A number of great IT and telecoms barristers.'
Legal 500 2010
'Top drawer IP set.'
Legal 500 2010
MedImmune v Novartis
Case Summary | 27 May 2011
Richard Meade QC and James Whyte acted for the claimant patentee in a patent infringement/revocation action concerning antibody phage display, in the first of a series of trials between the same parties around Europe. This technology was developed by the Medical Research Council and Cambridge Antibody Technology (now MedImmune) and provides a way to screen very large numbers of recombinant antibodies for those that bind to an antigen of interest, by displaying the antibodies on the protein coat of bacteriophage particles. The infringement claim related to Novartis’ drug Lucentis (ranibizumab) for wet age-related macular degeneration, which was alleged to be a direct product of the patented process. Argument on entitlement to priority and related SPC issues is due to take place in September 2011.